Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) reported fourth quarter and full-year 2025 financial results and provided updates on its clinical pipeline, including completion of enrollment for a Phase 3 …
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group …
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy Read More MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) will host a conference call and live webcast at 8:30 a.m. Eastern on Wednesday, March 4, 2026, to discuss its fourth-quarter and full-year …
Ocugen to Host March 4 Call on Q4 and Full-Year 2025 Results Read More MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced the appointment of Rita Johnson-Greene as chief financial officer.
Ocugen Appoints Rita Johnson-Greene as Chief Financial Officer Read More MALVERN, PA — On Friday, Ocugen (Nasdaq: OCGN) closed a $22.5 million registered direct stock offering, strengthening its balance sheet as the gene-therapy developer pushes forward with programs targeting blinding …
Ocugen Raises $20.9M to Extend Cash Runway Into Late 2026 Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness of its experimental gene therapy for Stargardt disease, a rare inherited …
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is stepping into one of biotech’s most important global spotlights, with its top executive set to present the company’s gene therapy strategy at …
Ocugen Eyes a Breakout Year as It Takes Center Stage at JPM Healthcare Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will present its latest advances in gene therapy for blindness diseases at NobleCon21, the annual emerging growth equity conference hosted by Noble Capital …
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported third-quarter 2025 financial results and provided an update on its advancing portfolio of late-stage gene therapies for inherited retinal diseases. The biotechnology …
Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones Read More